Core One Labs
Core One Labs is a Canadian biotechnology company specializing in the research, development, and production of psychedelic compounds for mental health and neurological disorders.
Company Overview
Core One Labs is a Canadian life sciences biotechnology company focused on the research, development, and production of biologically synthesized cGMP API grade psychedelic compounds. The company aims to become a vertically integrated large-scale supplier of these compounds to both individuals and corporations. With a presence on multiple stock exchanges—Canadian Securities Exchange (symbol 'COOL'), OTC (symbol 'CLABF'), and Borse Frankfurt Exchange (symbols 'LD6' and 'WKN: A3CSSU')—Core One Labs is positioned as a prominent player in the psychedelic compounds sector.
Business Units
Core One Labs operates three distinct business units: psychedelic compound production, drug development, and medical clinics. The psychedelic compound production unit includes subsidiaries Vocan Biotechnologies Inc., Awakened Biosciences Inc., and GMP Drug Inc. The drug development unit operates under Akome Biotech Ltd. The company’s medical clinics include Rejuva Mental Health Clinic, Bluejay Medical, and Shahcor clinics. These units collectively support Core One Labs’ mission to advance psychedelic compounds for mental health and neurological disorders.
Patent and Technology Development
Core One Labs has developed and filed for multiple patents to protect its innovative technologies. Through its subsidiary Vocan Biotechnologies Inc., the company has a proprietary psilocybin production system using engineered bacteria. Akome Biotech Ltd. holds four provisional patents for psychedelic-based pharmaceutical formulations targeting neurological and mental health disorders. Awakened Biosciences Inc. has filed three provisional patents for synthetic technologies for psilocybin and psilocin production methods.
Psychedelic Compound Production
Vocan Biotechnologies Inc., a subsidiary of Core One Labs, specializes in the production of psychedelic compounds. Recently, Vocan successfully tested its proof of concept for the biosynthesis of psilocybin and filed a patent application titled 'Production of Psychedelic Compounds'. The company’s state-of-the-art research facility enhances its capability to develop cost-effective production methods. Vocan's innovative psilocybin production method has the potential to significantly reduce production costs compared to traditional methods.
Medical Clinics and Patient Database
Core One Labs holds an interest in four medical clinics: Rejuva Mental Health Clinic, Bluejay Medical, and Shahcor clinics. These clinics maintain a comprehensive database of over 275,000 patients. This extensive patient database not only positions Core One Labs favorably in the healthcare sector but also provides a robust platform for the clinical research and advancement of psychedelic-based treatments. Through these clinics, the company aims to bring innovative mental health solutions to a broad patient population.